Loading...

Diabetes Cure or Diabetes Management?

2022-06-03T14:56:51+00:00Thought Leadership|

Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.

(more…)

LTEN 2022

2022-05-31T16:30:36+00:00Thought Leadership|

Are you attending LTEN June 13- June 15 in San Antonio, Texas?

Don’t miss our workshop “Biosimilars: Shifting Access Strategies in the Payer and Health Systems Market” on June 15 at at 2:00 pm featuring Precision’s Ryan Cox, Erica Gaeta, and Dan Vanderpoel.

(more…)

CMS Rule on Pharma Patient-Assistance Programs Could Cut Back on Aid

2022-05-17T14:28:45+00:00Thought Leadership|

A rule slated to take effect January 1, 2023 would reverse CMS’ long held position that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. The rule change could potentially result in increased patient out-of-pocket costs for drugs and pharma companies being on the hook for ensuring they know exactly where their assistance is going.

(more…)

CMS Targets Patient-Assistance Programs; Rule Could Curtail Aid

2022-04-18T18:16:37+00:00Thought Leadership|

CMS’s stance has long been that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. However, the rise of copayment accumulators and maximizers and health insurers’ subsequent taking of this assistance rather than allowing it to count toward patients’ deductibles and out-of-pocket maximums have caused the agency to rethink its position. Precision’s Ryan Cox and Reta Mourad break down the implications of the proposed rule change, including the potential for increased patient out-of-pocket drug costs, pharma companies being on the hook for ensuring they know exactly where their assistance is going, and possible unintended consequences.

(more…)

The Patient and Consumer Experience—The Core and Progress Duality for Successful and Sustainable Transformation

2022-03-22T15:02:36+00:00Thought Leadership|

Over the last decade, healthcare costs have continued to rise in the United States while outcomes have been stagnant and, in some cases, declined. Implementation of strategies around patient- or consumer-driven care has been a struggle as stakeholders try to define, measure, and improve the patient experience.

(more…)

Removal of the Medicaid Rebate Cap: Sensible or Nonsense?

2022-03-09T18:18:10+00:00Thought Leadership|

The American Rescue Plan of 2021 introduced a provision to remove the Medicaid Rebate Cap of 100%, effective January 2024. This legislation may turn profits upside down for a pharmaceutical company with a significant presence. Precision’s Cynthia Miller discusses what it would mean to remove the Medicaid Rebate Cap, how it would affect pharmaceutical companies, and strategies for moving forward.

(more…)

Load More Posts